Abstract. Many studies have indicated that nuclear DNA content evaluation can be used to predict biological behavior of transitional cell carcinoma (TCC) of the bladder. Some authors also indicated that static cytometry is more useful in DNA content analysis than flow cytometry. The aim of the present study was to evaluate the prognostic significance of DNA ploidy in TCC of the bladder, performed by using static cytometry with an image analyzer, and monitoring patients at 10 years follow-up. Thirty-one consecutive patients underwent transurethral or open surgery for bladder tumors, and neoplastic tissue samples taken from each patient were imprinted on glass slides and sent for histopathological and DNA content evaluation. DNA ploidy evaluation was performed using a CAS 200 image analyzer. Nuclear DNA content evaluation was compared to patient follow-up on recurrence, progression or survival performed 10 years after surgery. Pathological evaluation demonstrated the presence of superficial TCC in 23 patients, while 8 had an invasive bladder tumor. Twenty-nine tumor samples were adequate for DNA content measurement, with 13 showing diploid DNA content and 16 with aneuploid DNA content. At 10 years follow-up, all patients with aneuploid DNA content demonstrated a lower survival time (p=0.049) and higher recurrence rate (p=0.0346). A log-rank test demonstrated that stage, grade and nuclear DNA content are the most useful prognostic parameters for predicting the biological behavior of TCC of the bladder. These results confirm that static cytometry is a good and reliable method to evaluate DNA tumor content and considered a useful prognostic parameter for predicting recurrence rate, disease progression or survival in patients affected by bladder tumors.
Introduction
Transitional cell carcinoma of the bladder is a tumor with variable biological potential (1) ; the recurrence rate is 50% to 70% (2) and as many as 19% of pTa and 34% of pT1 tumors will progress to muscle-invasive features (3) . The ability to predict true tumor biological potential could facilitate patient treatment selection and improve the patient survival rate and quality of life.
Various pathological and clinical parameters, such as tumor grade, stage, multifocality, size, rate and pattern of recurrence, association with Cis and other dysplastic urothelial lesions have been associated with a poor clinical outcome (4) . Histopathological stage and grade are conventional prognostic factors for predicting biological behavior (5) .
To increase understanding of the cellular mechanisms underlying the development of bladder carcinoma and its natural history, many groups of potential molecular markers and quantitative morphometric methods have been described over the years (6) . DNA ploidy identification has been proposed (since the late 1970s) as a diagnostic (7) and prognostic method to evaluate the malignant potential in several neoplasms, such as ovarian (8) , endometrial (9) or colorectal cancers (10) . Moreover, other studies demonstrated that nuclear DNA content evaluation can be used to predict the risk of recurrence and progression of bladder carcinoma (11, 12) .
DNA content analysis can be performed using either flow cytometry or static cytometry with an image analyzer. Koss et al have demontrated that the percentage of aneuploid neoplasms seems to be lower when using flow cytometry instead of static cytometry (13) . This can be due to the presence of a high number of non-neoplastic diploid cells (such as lymphocytes) in the sample. Moreover, the prognostic significance of DNA static cytometry has not yet been prospectively studied in large groups of patients or with a long follow-up. The aim of this study was to evaluate the prognostic significance of DNA ploidy in transitional bladder cell carcinoma, using static cytometry with an image analyzer, and compare the results with the recurrence rate, progression and patient survival at 10 years follow-up. 
DNA analysis and test reading and interpretation.
For each slide, the cells were identified using an image analyzer, and more than 300 urothelial cell nuclei were selected and analyzed at a wavelength of 560 nm to integrate optical density, which is related to DNA content. Of 31 cases provided, 29 were suitable for measurement. Two cases were inadequate owing to the lack of cells on the slides. The DNA index (DI) and percentages of the G0/G1 cell peak and S and G2/M phases, and coefficient of variation (CV) of the representative peaks were assessed for each case. The diploid region limits were established on the basis of the control cell CV (≤5%). As the CV is equal to the ratio between standard deviation (SD) and the mean value, considering a double SD, the diploid range was between 0.90 and 1.10 and, consequently, the tetraploid range was between 1.80 and 2.20 (16) . The limits of the G0/G1 and G2 peaks of the tumor cells were obtained as in the control cells (±10% the modal value of the G0/G1 peak, calculated by means of the software utilized). In this way, it was possible to find the mean value of the DI and the percentage of cells included in the diploid, tetraploid, S-phase and hypertetraploid regions (16) .
DNA histograms were classified into two categories: diploid and aneuploid. The aneuploid tumor population was classified into four categories: triploid, multiploid, tetraploid and hypertetraploid. Diploid tumors included those with a G0/G1 peak, which fell within DI values of 1.00±10.0% (Fig. 1a ). Aneuploid were considered those presenting a G0/G1 peak with DI values greater than the diploid range (Fig. 1b) . Tetraploid tumors were considered a subset of DNA aneuploid tumors, where DI was 1.8-2.2 ( Fig. 1c ). Triploid were considered those presenting a DI intermediate between diploid and tetraploid limits (Fig. 1d ). Hypertetraploid were considered those presenting a DI >2.2 ( Fig. 1e) . Multiploid tumors presented a histogram with two consistent (>10%) aneuploid peaks or having consistent diploid and tetraploid peaks. ONCOLOGY REPORTS 15: 213-219, 2006 Table I. Summary of clinical and pathological patient data. 
sTCC, superficial transitional cell carcinoma; Cis, associated carcinoma in situ; TUR, transurethral resection.
Patient follow-up. For superficial bladder tumors, urine cytology, cystoscopy and complete blood tests were conducted 1 month after the conclusion of the treatment. In tumor-free cases, cystoscopy and urinary cytology were repeated at 3-monthly intervals for the first 2 years, at 6-monthly intervals for the next 3 years and annually thereafter. An ultrasound tomography of the urinary tract was required every 6 months.
Recurrence was defined as a positive finding in cystoscopy or bladder biopsy, while progression was defined as an increase in grade or stage of the tumor. The time to first recurrence was defined as the time from surgery until recurrence was detected during cystoscopy or primary cytology, as confirmed by multiple random bladder mucosa biopsies.
For invasive tumors, complete blood tests and urine analysis were performed 1 month after treatment. Serum creatinine and urea, blood gas analysis, sonography of the kidney, liver and retroperitoneum, and a chest-X-ray were repeated at 3-monthly intervals. A CT scan and bone scintigraphy were performed annually.
The follow-up was performed at 10 years (9-11 years). All patients were contacted by telephone, and tumor recurrence, progression and survival were evaluated.
Statistical analysis.
Fisher's exact test and the Chi-square test were used to assess the significance of all parameters, with P<0.05 accepted as significant. A univariate analysis of 
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P1, first cell peak; P2, second cell peak; P3, third cell peak; P4, fourth cell peak. C, number and percentage of cells within each cell peak. DI, mean DNA Index. With two cell peaks the first (P1) is considered G0/G1 phase, the second (P2) S-G2 phase. With more than two cell peaks, P1 and P2 are considered G0/G1 phase, while P3 and P4 are considered S-G2 phase. NA, not analyzable.
recurrence/progression was performed using the life-table method (log-rank analysis). Pearson's coefficient was adopted to evaluate the correlation between DNA content and all prognostic parameters in both superficial and invasive bladder cancer patients. Kaplan-Meier survival curves were also used to evaluate survival in superficial bladder cancers. The 95% CIs were calculated for the probability of survival for the Kaplan-Meier estimates. The Mann-Whitney test was also used to compare different parameter mean values. All statistical analyses were performed using SPSS 11.0 for AppleMacintosh (SPSS, Inc. Chicago, IL, USA).
Results
Twenty-two patients underwent TUR, while 9 patients had a radical cystectomy with non-continent urinary diversion. Histopathological examination demonstrated a superficial TCC in 23 patients (10 pTaG1, 4 pTaG2, 2 pT1G1, 5 pT1G2, and 2 pT1G3), while 8 had an invasive TCC (7 pT3G3 and 1 pT4G3). Follow-up ranged from 110-136 months (mean ± SD, 127.20±4.92) ( Table I ). The mean of slides analyzed was 2.77 (range, 1 to 6) for each patient. In 29 out of 31 patients, it was technically possible to perform adequate DNA content measurements, while in 2/31 (pTaG1-pT1G2) there was no tumor DNA analysis due to technical problems or an insufficient number of tumor cells on the slides. All patients had a complete clinical follow-up and were available for the study.
The mean DNA content (DNA index) of all tumor samples ranged from 0.98 to 3.04 (mean 1.50±0.63) when compared to granulocytes, lymphocytes and normal urothelial cells. Thirteen out of 29 patients (44.8%) showed normal DNA content (ranging from 0.98 to 1.03, mean 1.00±0.01) and were classified as diploid. Sixteen patients (55.2%) showed DNA content ranging from 1.40 to 3.04 (mean 1.91±0.58) and were classified as aneuploid.
The aneuploid tumor population showed 4 triploid tumors (mean 1.57±0.15), 3 tetraploid tumors (mean 1.93±0.03), 6 multiploid tumors (multiple stemline DNA distribution) (first peak mean of 1.00±0.03 and second peak mean of 1.90±0.09), and 3 hypertetraploid tumors (mean 2.83±0.27) ( Table II) . Stratification according to grade showed that 8 out of 11 G1 presented normal DNA content, while 2 presented multiploid DNA content and 1 tetraploid with DNA content. Of 8 G2 tumors, 5 were classified as diploid, 2 as triploid and 1 as multiploid. Among G3 tumors, no case presented normal DNA content; 2 were multiploid, 2 tetraploid, 2 triploid and 4 hypertetraploid.
A statistically significant correlation was reported between grade and DNA content (r=0.658, p≤0.0001). Stratification according to stage showed that 10 out of 13 pTa presented normal DNA content, while 2 presented multiploid and 1 presented tetraploid DNA content. Of 8 pT1 cases, 3 were classified as diploid, 2 as multiploid, 2 as triploid and 1 as tetraploid. No pT3 presented normal DNA content; 2 were triploid, 1 multiploid, 1 tetraploid and 3 hypertetraploid. The pT4 presented hypertetraploid DNA content.
A strong correlation was reported between stage and DNA content (r=0.767, p≤0.0001). No significant correlation between DNA content and other prognostic parameters (such as multiplicity, size or associated Cis) was reported.
The follow-up showed that 5 out of 13 patients with diploid DNA content were alive with no evidence of disease (NED) at a mean time of 131.8 months (range, 118 to 138 months) (4 pTaG1 and 1 pTaG2), 4 out of 13 (3 pTaG1 and 1pTaG2) were alive with NED and a previous single or multiple recurrence(s) invariably treated by TUR (with no progression in stage and grade) at a mean time of 116.5 months (range, 110 to 124 months), 2 out of 13 died due to unrelated causes and 2 out of 13 died of disease progression (1 pT1G1 and 1 pT1G2) at 121 and 48 months. Of 16 patients with aneuploid DNA content, 13 died of disease progression at a mean time of 54 months (range, 18 to 136 months).
One out of 16 patients died due to unrelated causes at 72 months, while 2 out of 16 were alive with NED and a previous single or multiple recurrence(s) invariably treated by TUR (with no progression in stage and grade) at 115 and 138 months (pT1G1 and pTaG1). DNA content analysis in the aneuploid tumor population showed that all of those with triploid tumors died at a mean time of 70.25 months (range, 36 to 111 months) (2pT1G2 and 2pT3G3), 2 out of 3 tetraploid tumors died of disease progression at 18 and 89 months (pT1G3 and pT3G3), all hypertetraploid patients died of disease progression at a mean time of 24.75 months (range, 21 to 31 months) (3pT3G3 and pT4G3) and 3 out of 5 multiploid tumor patients died of disease progression at 23, 56 and 136 months respectively (pTaG2, pT1G3, and pT3G3).
The survival analysis, performed with Kaplan-Meier curves, demonstrated a statistically significant difference between patients with normal DNA content (DI 0.90-1.10) and those with aneuploid DNA content (DI >1.10) in superficial TCC (p=0.049) (Fig. 2) . No significant difference between patients with a normal DNA content and those with aneuploid DNA content was reported in invasive TCC. Four out of 13 diploid patients presented a mean recurrence rate of 5.8 months (range, 1 to 9 months) with a mean time of 7.8 months at first recurrence (range, 5 to 13 months). Two out Relationship between recurrence-free patient survival (%) and cause-specific survival in accordance with DNA content. of 16 aneuploid patients presented a recurrence rate of 5 and 7 months, with the first recurrence at 3 and 5 months. The DNA content status showed a statistically significant correlation with recurrence (p=0.0346).
Univariate analysis, performed with a log-rank test, demonstrated that stage, grade and DNA content are the most useful prognostic parameters for predicting the biological behavior of transitional cell carcinoma of the bladder (Table III) .
Discussion
DNA tumor content evaluation is considered a good prognostic factor in transitional cell carcinoma (17, 18) . However, it is rarely used due to technical difficulties, either in sample preparation and analysis or in choosing the right method to evaluate the samples.
Flow cytometry results are considered to be less reliable compared with static cytometry, due to the presence of nonneoplastic cells (lymphocytes) in the cellular suspension used for tumor DNA evaluation (19) . On the other hand, static cytometry allows direct evaluation of tumor cell selection of at least 300 or 400 tumor cell nuclei.
In the present study, we evaluated 29 patients affected by transitional cell carcinoma of the bladder, comparing the mean DNA content of their tumors with recurrence or progression of disease at 10 years follow-up. Although the prognosis of patients with a diploid DNA content was better than those with aneuploid content, we found a strong correlation between grade (r=0.658, p<0.0001) and stage (r=0.767, p<0.0001).
Superficial and/or low grade tumors presented a prevalent diploid DNA content, while the invasive or high grade ones were mainly aneuploid. Nevertheless 2 out 16 aneuploid patients were alive with no evidence of disease. Their tumor stages were T1G1 and TaG1, respectively. In these cases, pathological tumor stage and grade appear to be stronger prognostic factors than tumor DNA content evaluation. These results are comparable with those reported in other studies (20) . Joachim-Liossi et al demonstrated a strong correlation between recurrence status and DNA ploidy (p<0.001) in 80 patients with superficial transitional cell carcinoma of the bladder (17) .
On the other hand, no correlation was found between DNA content and other prognostic parameters, such as multifocality, tumor size or associated carcinoma in situ. In 1994, Al-Abadi et al demonstrated a statistically significant correlation between tumor ploidy and disease recurrence or progression. They found that tumor DNA content was the strongest predictor of patient survival (21) . The patients affected by superficial tumors evaluated in our study presented a significant impact of tumor DNA content both on the survival and recurrence rate at 10 years follow-up (p=0.048 and p=0.0346 respectively). These data were confirmed by univariate analysis.
In conclusion, static cytometry is a good and reliable method to evaluate DNA tumor content in transitional cell carcinoma. It is a useful prognostic parameter for predicting the recurrence rate in superficial tumors and disease progression or survival in patients affected by invasive tumors. However, the method is time-consuming and requires adequate instrumentation and funding. Table III . Univariate analysis of factors affecting recurrencefree survival.
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